Deciding when to discontinue maintenance therapy in a patient with multiple myeloma
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-01-15
Просмотров: 99
In this video, Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses factors to consider when deciding whether discontinue maintenance therapy in a patient with multiple myeloma (MM), emphasizing that they must achieve and sustain measurable residual disease (MRD) negativity for at least two years before discontinuation can be considered. Prof. San Miguel highlights that the decision to stop treatment should also be based on the absence of high-risk factors, including late achievement of MRD negativity, high-risk genetics, and a high number of circulating tumor cells (CTCs) at diagnosis. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
